



**FOR IMMEDIATE RELEASE**  
5th December 2006

## **OXFORD GENE TECHNOLOGY JOINS CHAVI FUNDED PROJECT TO PROVIDE MICROARRAYS FOR HIV VACCINE RESEARCH**

**Oxford, December 5, 2006** – Oxford Gene Technology (OGT) is pleased to announce that it has been selected to design and fabricate microarrays for the Innate Discovery Team as part of the Centre for HIV-AIDS Vaccine Immunology (CHAVI) research project to develop vaccines for HIV. The team is led by Professor Andrew McMichael, senior scientific leader, Oxford University and Dr Persephone Borrow of the Edward Jenner Institute.

OGT will design and develop a high quality optimised oligonucleotide microarray to study genes of interest involved in the cellular immune response in early stage HIV infected patients. The microarrays will be printed using the OGT ink jet *in-situ* synthesis (IJSS) platform and will investigate the use of its Multi Sample Array (MSA) format enabling the parallel analysis of multiple samples. This will effectively reduce the cost per sample and speed up sample processing time.

Mr James Clough, Commercial Director at OGT said: “We are very excited to be working with Professor McMichael’s team and the wider CHAVI network. OGT’s complete microarray solution combines its bioinformatics expertise with innovative microarray technology and is well suited to the project task.”

**- ENDS -**

## For further information, please contact:

### At Oxford Gene Technology:

Nicola Booton-Mander, Marketing Manager

Oxford Gene Technology

Begbroke Science Park,

Sandy Lane, Yarnton

Oxford OX5 1PF

T: +44 1865 856352

F: +44 1865 842116

E: [licensing@ogt.co.uk](mailto:licensing@ogt.co.uk)

W: [www.ogt.co.uk](http://www.ogt.co.uk)

### Media Enquiries:

Annabel Entress, 0207 886 8150 / [a.entress@northbankcommunications.com](mailto:a.entress@northbankcommunications.com)

Sarah Jeffery, 0207 886 8150 / [s.jeffery@northbankcommunications.com](mailto:s.jeffery@northbankcommunications.com)

## Notes to editors

### About Oxford Gene Technology

- Founded in 1995 by the pioneer of Southern Blotting, Professor Sir Edwin Southern, OGT operates out of Begbroke Business Park near Oxford, with excellent access to a growing network of life science companies
- OGT offers a comprehensive custom microarray consultancy service, from experimental design through all stages to data analysis and interpretation. It has a strong proven track record in providing custom microarray service in a range of applications, and recently announced the launch of its first microarray product, an *Escherichia coli* K12 ChIP on chip, the first ChIP microarray product to be launched as part of OGT's Prokaryotic Chip<sup>2</sup> family

### The key focus areas of OGT include:

1. **Array-based application products and services** for life science research and molecular diagnostics. OGT's flexible and cost-effective, customised DNA microarray service covers a range of applications, offering specialist support and assisting customers with every aspect of their research, from initial consultation and experimental design to probe selection, array design and fabrication through to data analysis and interpretation
2. **Development of innovative platform products** for clinical research and diagnostics
3. **Licensing.** OGT operates an open licensing policy which has successfully provided access for a number of companies to OGT's fundamental intellectual property, particularly in the area of microarrays
4. **Scientific collaborations** to generate diagnostic biomarker intellectual property

For further information on OGT visit <http://www.ogt.co.uk/>

- ENDS -